Systems, products, compounds and methods can be applied and/or used by a person to facilitate and promote the production of nitric oxide to be used by a person for health benefits. The systems, products, and devices include a nitric oxide nasal delivery system. The system can comprise one or more containers for compounds that when mixed are adapted to produce nitric oxide gas, at least one container with a nitrite powder and an acidic powder. The nitric oxide gas may then be delivered to a user via one or more of the nasal cavities and/or mouth.

Systems, products, compounds and methods can be applied and/or used by a person to facilitate and promote the production of nitric oxide to be used by a person for health benefits. The systems, products, and devices include a nitric oxide nasal delivery system. The system can comprise one or more containers for compounds that when mixed are adapted to produce nitric oxide gas, at least one container with a nitrite powder and an acidic powder. The nitric oxide gas may then be delivered to a user via one or more of the nasal cavities and/or mouth.

Inhalation of low levels of nitric oxide can rapidly and safely decrease pulmonary hypertension in mammals. A nitric oxide delivery system that converts nitrogen dioxide to nitric oxide employs a surface-active material, such as silica gel, coated with an aqueous solution of antioxidant, such as ascorbic acid.

Inhalation of low levels of nitric oxide can rapidly and safely decrease pulmonary hypertension in mammals. A nitric oxide delivery system that converts nitrogen dioxide to nitric oxide employs a surface-active material, such as silica gel, coated with an aqueous solution of antioxidant, such as ascorbic acid.

A nitric oxide administration device 25 includes a second flow path 201 including an intake port 201a and an NO supply port 201b, a discharge unit 205 which is arranged in the second flow path 201 and which generates NO from air introduced via the intake port 201a, generated NO being supplied via the NO supply port 201b, an NO.sub.2 adsorption unit 206 which is arranged downstream of the discharge unit 205 and which removes NO.sub.2, an NO densitometer 208 which is arranged downstream of the discharge unit 205 or which is arranged in a flow path for reflux from downstream of the NO.sub.2 adsorption unit 206 to upstream of the NO.sub.2 adsorption unit 206, and a concentration estimation unit 301 which estimates an NO concentration and an NO.sub.2 concentration in a predetermined position based on an oxygen concentration in the atmosphere or the second flow path 201, an NO concentration measured by the NO densitometer 208, and a residence time of gas containing NO in the second flow path 201 between the NO.sub.2 adsorption unit 206 and the predetermined position.

Inhalation of low levels of nitric oxide can rapidly and safely decrease pulmonary hypertension in mammals. A nitric oxide delivery system that converts nitrogen dioxide to nitric oxide employs a surface-active material, such as silica gel, coated with an aqueous solution of antioxidant, such as ascorbic acid.

Inhalation of low levels of nitric oxide can rapidly and safely decrease pulmonary hypertension in mammals. A nitric oxide delivery system that converts nitrogen dioxide to nitric oxide employs a surface-active material, such as silica gel, coated with an aqueous solution of antioxidant, such as ascorbic acid.

Inhalation of low levels of nitric oxide can rapidly and safely decrease pulmonary hypertension in mammals. A nitric oxide delivery system that converts nitrogen dioxide to nitric oxide employs a surface-active material, such as silica gel, coated with an aqueous solution of antioxidant, such as ascorbic acid.

Inhalation of low levels of nitric oxide can rapidly and safely decrease pulmonary hypertension in mammals. A nitric oxide delivery system that converts nitrogen dioxide to nitric oxide employs a surface-active material, such as silica gel, coated with an aqueous solution of antioxidant, such as ascorbic acid.

The present invention relates to a liquid nitric oxide releasing solution (NORS) comprised of at least one nitric oxide releasing compound and at least one acidifying agent, wherein the NORS provides an extended release of a therapeutically effective amount of nitric oxide gas (gNO). The present invention also relates to a liquid NORS comprised of at least one nitrite compound having a concentration of no greater than about 0.5% w/v and at least one acidifying agent, wherein the NORS releases a therapeutically effective amount of gNO. The present invention also relates to a method for the treatment of a wound in a human, the method comprising administering to the human a liquid NORS comprised of at least one nitric oxide releasing compound and at least one acidifying agent, wherein the NORS provides an extended release of a therapeutically effective amount of gNO. The present invention also relates to a method for the treatment, prevention, or reduction of incidence of a disease or disorder in a human in need thereof, the method comprising administering to the human a liquid NORS comprised of at least one nitrite compound at a concentration of no greater than about 0.5% w/v and at least one acidifying agent, wherein the NORS releases a therapeutically effective amount of gNO.